pharma news today obesity drug glp-1 Many people start and stop GLP-1s. Here's why that may be a bad idea : NPR Obesity Clinical Trials | Expert

This work was supported by the National Institute of Diabetes, Digestive and Kidney Diseases R00DK1208689 and P30DK045735 grants, the National Institute of Health Yale-Murine Tissue Mapping Center Grant U54 AG079759 and the National Institute of Health National Institutes of Aging Grant P30AG066508

Load bearing is shifted to the posterior elements, resulting in facet hypertrophy and osteoarthritic changes secondary to the increased load borne by the facet joints

Halfway between knee and hip, on the outer front area where you can easily pinch a fold of skin

There are also risks to taking the drugs for people with disordered eating, especially since patients are not evaluated for these disorders when prescribed GLP-1 drugs